Animal models of mucositis: Critical tools for advancing pathobiological understanding and identifying therapeutic targets

Current Opinion in Supportive and Palliative Care

Volumn 13, Issue 2, 2019, Pages 119-133

  Wardill, Hannah R ^a,c   Tissing, Wim J E ^c,d   Kissow, Hannelouise ^e   Stringer, Andrea M ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d Department of Radiation Oncology   (Netherlands)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

animal models; mucositis; pathobiology; preclinical

Indexed keywords

ANTINEOPLASTIC AGENT;

ANIMAL; DISEASE MODEL; DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; MUCOSA INFLAMMATION; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; STOMATITIS;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; GASTROINTESTINAL DISEASES; MUCOSITIS; SEVERITY OF ILLNESS INDEX; STOMATITIS;

EID: 85065509408     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0000000000000421     Document Type: Review

References (171)

1. Carlotto A, Hogsett VL, Maiorini EM,. The economic burden of toxicities associated with cancer treatment: review of the literature and analysis of nausea and vomiting, diarrhoea, oral mucositis and fatigue. Pharmacoeconomics 2013; 31: 753-766.
2. Sonis ST,. Oral mucositis in cancer therapy. J Support Oncol 2004; 2 (6 Suppl 3): 3-8.
3. Al-Dasooqi N, Sonis ST, Bowen JM,. Emerging evidence on the pathobiology of mucositis. Support Care Cancer 2013; 21: 2075-2083.
4. Andreyev J, Ross P, Donnellan C,. Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncol 2014; 15: e447-e460.
5. Lalla RV, Bowen J, Barasch A,. Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 2014; 120: 1453-1461.
6. Thirion-Delalande C, Gervais F, Fisch C,. Comparative analysis of the oral mucosae from rodents and nonrodents: application to the nonclinical evaluation of sublingual immunotherapy products. PLoS One 2017; 12: e0183398.
7. Montenegro MF, Sundqvist ML, Nihlen C,. Profound differences between humans and rodents in the ability to concentrate salivary nitrate: Implications for translational research. Redox Biol 2016; 10: 206-210.
8. Al-Azri AR, Gibson RJ, Bowen JM,. Involvement of matrix metalloproteinases (MMP-3 and MMP-9) in the pathogenesis of irinotecan-induced oral mucositis. J Oral Pathol Med 2014; 44: 459-467.
9. Sonis ST, Tracey C, Shklar G,. An animal model for mucositis induced by cancer chemotherapy. Oral Surg Oral Med Oral Pathol 1990; 69: 437-443.
10. Dorr W, Spekl K, Farrell CL,. Amelioration of acute oral mucositis by keratinocyte growth factor: fractionated irradiation. Int J Radiat Oncol Biol Phys 2002; 54: 245-251.
11. Watanabe S, Suemaru K, Nakanishi M,. Assessment of the hamster cheek pouch as a model for radiation-induced oral mucositis, and evaluation of the protective effects of keratinocyte growth factor using this model. Int J Radiat Biol 2014; 90: 884-891.
12. Toshkov IA, Gleiberman AS, Mett VL,. Mitigation of radiation-induced epithelial damage by the TLR5 agonist entolimod in a mouse model of fractionated head and neck irradiation. Radiat Res 2017; 187: 570-580.
13. Wu X, Chen P, Sonis ST,. A novel Peptide to treat oral mucositis blocks endothelial and epithelial cell apoptosis. Int J Radiat Oncol Biol Phys 2012; 83: e409-e415.
14. Han G, Bian L, Li F,. Preventive and therapeutic effects of Smad7 on radiation-induced oral mucositis. Nat Med 2013; 19: 421-428.
15. Watkins B, Pouliot K, Fey E,. Attenuation of radiation-and chemoradiation-induced mucositis using gamma-D-glutamyl-L-tryptophan (SCV-07). Oral Dis 2010; 16: 655-660.
16. Sonis ST, Van Vugt AG, Brien JP,. Transforming growth factor-beta 3 mediated modulation of cell cycling and attenuation of 5-fluorouracil induced oral mucositis. Oral Oncol 1997; 33: 47-54.
17. Clarke J, Butler R, Howarth G,. Exposure of oral mucosa to bioactive milk factors reduces severity of chemotherapy-induced mucositis in the hamster. Oral Oncol 2002; 38: 478-485.
18. Takeuchi I, Kamiki Y, Makino K,. Therapeutic efficacy of rebamipide-loaded PLGA nanoparticles coated with chitosan in a mouse model for oral mucositis induced by cancer chemotherapy. Colloids Surf B Biointerfaces 2018; 167: 468-473.
19. Shimamura Y, Takeuchi I, Terada H, Makino K,. A mouse model for oral mucositis induced by cancer chemotherapy. Anticancer Res 2018; 38: 307-312.
20. Shimamura Y, Takeuchi I, Terada H, Makino K,. Therapeutic effect of GGsTop, selective gamma-glutamyl transpeptidase inhibitor, on a mouse model of 5-fluorouracil-induced oral mucositis. Anticancer Res 2019; 39: 201-206.
21. Bayer S, Kazancioglu HO, Acar AH,. Comparison of laser and ozone treatments on oral mucositis in an experimental model. Lasers Med Sci 2017; 32: 673-677.
22. Tancharoen S, Shakya P, Narkpinit S,. Anthocyanins extracted from Oryza sativa L. prevent fluorouracil-induced nuclear factor-kappab activation in oral mucositis: in vitro and in vivo studies. Int J Mol Sci 2018; 19: pii: E2981.
23. Ara G, Watkins BA, Zhong H,. Velafermin (rhFGF-20) reduces the severity and duration of hamster cheek pouch mucositis induced by fractionated radiation. Int J Radiat Biol 2008; 84: 401-412.
24. Sonis ST,. Animal models of oral mucositis induced by antineoplastic drugs and radiation. Totoaw, NJ: Humana Press; 2002.
25. Sonis ST,. The pathobiology of mucositis. Nat Rev Cancer 2004; 4: 277-284.
26. Caluwaerts S, Vandenbroucke K, Steidler L,. AG013, a mouth rinse formulation of Lactococcus lactis secreting human Trefoil Factor 1, provides a safe and efficacious therapeutic tool for treating oral mucositis. Oral Oncol 2010; 46: 564-570.
27. Hwang D, Popat R, Bragdon C,. Effects of ceramide inhibition on experimental radiation-induced oral mucositis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005; 100: 321-329.
28. Alvarez E, Fey EG, Valax P,. Preclinical characterization of CG53135 (FGF-20) in radiation and concomitant chemotherapy/radiation-induced oral mucositis. Clin Cancer Res 2003; 9: 3454-3461.
29. Sonis ST, Costa JW Jr, Evitts SM,. Effect of epidermal growth factor on ulcerative mucositis in hamsters that receive cancer chemotherapy. Oral Surg Oral Med Oral Pathol 1992; 74: 749-755.
30. Sonis ST, Van Vugt AG, McDonald J,. Mitigating effects of interleukin 11 on consecutive courses of 5-fluorouracil-induced ulcerative mucositis in hamsters. Cytokine 1997; 9: 605-612.
31. Dorr W, Spekl K, Farrell CL,. The effect of keratinocyte growth factor on healing of manifest radiation ulcers in mouse tongue epithelium. Cell Prolif 2002; 35 (Suppl 1): 86-92.
32. Dorr W, Brankovic K, Hartmann B,. Repopulation in mouse oral mucosa: changes in the effect of dose fractionation. Int J Radiat Biol 2000; 76: 383-390.
33. Haagen J, Krohn H, Rollig S,. Effect of selective inhibitors of inflammation on oral mucositis: preclinical studies. Radiother Oncol 2009; 92: 472-476.
34. Secombe KR, Coller JK, Gibson RJ,. The bidirectional interaction of the gut microbiome and the innate immune system: implications for chemotherapy-induced gastrointestinal toxicity. Int J Cancer 2018; doi: 10.1002/ijc.31836. [Epub ahead of print].
35. Aricibasi M, Jung A, Heller ED,. Differences in genetic background influence the induction of innate and acquired immune responses in chickens depending on the virulence of the infecting infectious bursal disease virus (IBDV) strain. Vet Immunol Immunopathol 2010; 135: 79-92.
36. Voss G, Dittmer U, Coulibaly C,. Differences in the B and T cell immune response to the envelope glycoprotein 130 (gp130) of the macaque strain of simian immunodeficiency virus (SIVmac), induced by immunization of rhesus macaques with virus-derived or vaccinia virus-expressed gp130. J Gen Virol 1993; 74 (Pt 9): 1757-1763.
37. Blagojevic V, Kovacevic-Jovanovic V, Curuvija I,. Rat strain differences in peritoneal immune cell response to selected gut microbiota: a crossroad between tolerance and autoimmunity? Life Sci 2018; 197: 147-157.
38. Kuiken NS, Rings EH, Havinga R,. Effect of minimal enteral feeding on recovery in a methotrexate-induced gastrointestinal mucositis rat model. Support Care Cancer 2016; 24: 1357-1364.
39. Kolli VK, Natarajan K, Isaac B,. Mitochondrial dysfunction and respiratory chain defects in a rodent model of methotrexate-induced enteritis. Hum Exp Toxicol 2014. 1051-1065.
40. Sukhotnik I, Moati D, Shaoul R,. Quercetin prevents small intestinal damage and enhances intestinal recovery during methotrexate-induced intestinal mucositis of rats. Food Nutr Res 2018; 62: 1327. doi: 10.29219/fnr.v62.1327.
41. Ben-Lulu S, Pollak Y, Mogilner J,. Dietary transforming growth factor-beta 2 (TGF-beta2) supplementation reduces methotrexate-induced intestinal mucosal injury in a rat. PLoS One 2012; 7: e45221.
42. Gibson RJ, van Sebille YZA, Wardill HR,. Selective MMP inhibition, using AZD3342, to reduce gastrointestinal toxicity and enhance chemoefficacy in a rat model. Chemotherapy 2019; 63: 284-292.
43. de Koning BA, Sluis M, Lindenbergh-Kortleve DJ,. Methotrexate-induced mucositis in mucin 2-deficient mice. J Cell Physiol 2007; 210: 144-152.
44. Chen C, Tian L, Zhang M,. Protective effect of amifostine on high-dose methotrexate-induced small intestinal mucositis in mice. Dig Dis Sci 2013; 58: 3134-3143.
45. Mauger CA, Butler RN, Geier MS,. Probiotic effects on 5-fluorouracil-induced mucositis assessed by the sucrose breath test in rats. Dig Dis Sci 2007; 52: 612-619.
46. Mashtoub S, Lampton LS, Eden GL,. Emu oil combined with lyprinol reduces small intestinal damage in a rat model of chemotherapy-induced mucositis. Nutr Cancer 2016; 68: 1171-1180.
47. Zhang S, Liu Y, Xiang D,. Assessment of dose-response relationship of 5-fluorouracil to murine intestinal injury. Biomed Pharmacother 2018; 106: 910-916.
48. Huang L, Chiang Chiau JS, Cheng ML,. SCID/NOD mice model for 5-FU induced intestinal mucositis: safety and effects of probiotics as therapy. Pediatr Neonatol 2018; doi: 10.1016/j.pedneo.2018.07.007. [Epub ahead of print].
49. Wang C, Huo X, Gao L,. Hepatoprotective effect of carboxymethyl pachyman in fluorouracil-treated CT26-bearing mice. Molecules 2017; 22: E756.
50. Liu Z, Xie W, Li M,. Oral administration of polaprezinc attenuates fluorouracil-induced intestinal mucositis in a mouse model. Basic Clin Pharmacol Toxicol 2017; 121: 480-486.
51. Manzano M, Bueno P, Rueda R,. Intestinal toxicity induced by 5-fluorouracil in pigs: a new preclinical model. Chemotherapy 2007; 53: 344-355.
52. Gibson RJ, Bowen JM, Alvarez E,. Establishment of a single-dose irinotecan model of gastrointestinal mucositis. Chemotherapy 2007; 53: 360-369.
53. Arifa RDN, Paula TP, Madeira MFM,. The reduction of oxidative stress by nanocomposite Fullerol decreases mucositis severity and reverts leukopenia induced by Irinotecan. Pharmacol Res 2016; 107: 102-110.
54. Sezer A, Usta U, Cicin I,. The effect of Saccharomyces boulardii on reducing irinotecan-induced intestinal mucositis and diarrhea. Med Oncol 2009; 26: 350-357.
55. Cechinel-Zanchett CC, Boeing T, Somensi LB,. Flavonoid-rich fraction of Bauhinia forficata Link leaves prevents the intestinal toxic effects of irinotecan chemotherapy in IEC-6 cells and in mice. Phytother Res 2019; 33: 3390-3406.
56. Nogueira LT, Costa DV, Gomes AS,. The involvement of mast cells in the irinotecan-induced enteric neurons loss and reactive gliosis. J Neuroinflammation 2017; 14: 79.
57. Wardill HR, Gibson RJ, Van Sebille YZ,. Irinotecan-induced gastrointestinal dysfunction and pain are mediated by common TLR4-dependent mechanisms. Mol Cancer Ther 2016; 15: 1376-1386.
58. Wang X, Zhu S, Qian L,. IL-1Ra selectively protects intestinal crypt epithelial cells, but not tumor cells, from chemotoxicity via p53-mediated upregulation of p21 (WAF1) and p27 (KIP1). Pharmacol Res 2014; 82: 21-33.
59. Ikuno N, Soda H, Watanabe M, Oka M,. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J Natl Cancer Inst 1995; 87: 1876-1883.
60. McQuade RM, Stojanovska V, Stavely R,. Oxaliplatin-induced enteric neuronal loss and intestinal dysfunction is prevented by co-treatment with BGP-15. Br J Pharmacol 2018; 175: 656-677.
61. Stojanovska V, McQuade RM, Fraser S,. Oxaliplatin-induced changes in microbiota, TLR4+ cells and enhanced HMGB1 expression in the murine colon. PLoS One 2018; 13: e0198359.
62. Wang H, Brook CL, Whittaker AL,. Effects of Streptococcus thermophilus TH-4 in a rat model of doxorubicin-induced mucositis. Scand J Gastroenterol 2013; 48: 959-968.
63. Rigby RJ, Carr J, Orgel K,. Intestinal bacteria are necessary for doxorubicin-induced intestinal damage but not for doxorubicin-induced apoptosis. Gut Microbes 2016; 7: 414-423.
64. de Koning BA, Lindenbergh-Kortleve DJ, Pieters R,. Alterations in epithelial and mesenchymal intestinal gene expression during doxorubicin-induced mucositis in mice. Dig Dis Sci 2007; 52: 1814-1825.
65. Cardani D, Sardi C, La Ferla B,. Sodium glucose cotransporter 1 ligand BLF501 as a novel tool for management of gastrointestinal mucositis. Mol Cancer 2014; 13: 23.
66. Martin J, Howard SC, Pillai A,. The weaned pig as a model for doxorubicin-induced mucositis. Chemotherapy 2014; 60: 24-36.
67. Shen RL, Pontoppidan PE, Rathe M,. Milk diets influence doxorubicin-induced intestinal toxicity in piglets. Am J Physiol Gastrointest Liver Physiol 2016; 311: G324-G333.
68. Pontoppidan PL, Shen RL, Petersen BL,. Intestinal response to myeloablative chemotherapy in piglets. Exp Biol Med (Maywood) 2014; 239: 94-104.
69. Pereira VB, Melo AT, Assis-Junior EM,. A new animal model of intestinal mucositis induced by the combination of irinotecan and 5-fluorouracil in mice. Cancer Chemother Pharmacol 2016; 77: 323-332.
70. Mi H, Dong Y, Zhang B,. Bifidobacterium infantis ameliorates chemotherapy-induced intestinal mucositis via regulating T cell immunity in colorectal cancer rats. Cell Physiol Biochem 2017; 42: 2330-2341.
71. Bull C, Malipatlolla D, Kalm M,. A novel mouse model of radiation-induced cancer survivorship diseases of the gut. Am J Physiol Gastrointest Liver Physiol 2017; 313: G456-G466.
72. Yeoh AS, Gibson RJ, Yeoh EE,. A novel animal model to investigate fractionated radiotherapy-induced alimentary mucositis: the role of apoptosis, p53, nuclear factor-kappaB, COX-1, and COX-2. Mol Cancer Ther 2007; 6: 2319-2327.
73. Fijlstra M, Schierbeek H, Voortman G,. Continuous enteral administration can enable normal amino acid absorption in rats with methotrexate-induced gastrointestinal mucositis. J Nutr 2012; 142: 1983-1990.
74. Fijlstra M, Rings EH, van Dijk TH,. Continuous enteral administration can overcome the limited capacity to absorb glucose in rats with methotrexate-induced gastrointestinal mucositis. Support Care Cancer 2013; 21: 863-871.
75. Kuiken NS, Rings EH, Havinga R,. Effect of oral insulin on the severity and recovery of methotrexate-induced gastrointestinal mucositis in the rat. J Pediatr Gastroenterol Nutr 2017; 64: e27-e32.
76. Kuiken NSS, Rings E, Alffenaar JC,. Tumor necrosis factor-alpha inhibitor etanercept does not alter methotrexate-induced gastrointestinal mucositis in rats. J Pediatr Gastroenterol Nutr 2017; 65: e28-e34.
77. Kuiken NSS, Rings E, Blijlevens NMA,. Biomarkers and noninvasive tests for gastrointestinal mucositis. Support Care Cancer 2017; 25: 2933-2941.
78. Sukhotnik I, Geyer T, Pollak Y,. The role of Wnt/beta-catenin signaling in enterocyte turnover during methotrexate-induced intestinal mucositis in a rat. PLoS One 2014; 9: e110675.
79. Sukhotnik I, Mogilner JG, Shteinberg D,. Leptin accelerates enterocyte turnover during methotrexate-induced intestinal mucositis in a rat. Cancer Biol Ther 2009; 8: 899-906.
80. Koppelmann T, Pollak Y, Mogilner J,. Dietary L-arginine supplementation reduces methotrexate-induced intestinal mucosal injury in rat. BMC Gastroenterol 2012; 12: 41.
81. Sukhotnik I, Mogilner JG, Karry R,. Effect of oral glutamine on enterocyte turnover during methotrexate-induced mucositis in rats. Digestion 2009; 79: 5-13.
82. Sukhotnik I, Shteinberg D, Ben Lulu S,. Effect of transforming growth factor-alpha on enterocyte apoptosis is correlated with EGF receptor expression along the villus-crypt axis during methotrexate-induced intestinal mucositis in a rat. Apoptosis 2008; 13: 1344-1355.
83. Shaoul R, Moati D, Schwartz B,. Effect of pomegranate juice on intestinal recovery following methotrexate-induced intestinal damage in a rat model. J Am Coll Nutr 2018; 37: 406-414.
84. Sukhotnik I, Shehadeh N, Coran AG,. Oral insulin enhances cell proliferation and decreases enterocyte apoptosis during methotrexate-induced mucositis in the rat. J Pediatr Gastroenterol Nutr 2008; 47: 115-122.
85. Carneiro-Filho BA, Lima IP, Araujo DH,. Intestinal barrier function and secretion in methotrexate-induced rat intestinal mucositis. Dig Dis Sci 2004; 49: 65-72.
86. de Araujo AA, Borba PB, de Souza FH,. In a methotrexate-induced model of intestinal mucositis, olmesartan reduced inflammation and induced enteropathy characterized by severe diarrhea, weight loss, and reduced sucrose activity. Biol Pharm Bull 2015; 38: 746-752.
87. Francois M, Takagi K, Legrand R,. Increased ghrelin but low ghrelin-reactive immunoglobulins in a rat model of methotrexate chemotherapy-induced anorexia. Front Nutr 2016; 3: 23.
88. Whittaker AL, Zhu Y, Howarth GS,. Effects of commercially produced almond by-products on chemotherapy-induced mucositis in rats. World J Gastrointest Pathophysiol 2017; 8: 176-187.
89. Whitford EJ, Cummins AG, Butler RN,. Effects of Streptococcus thermophilus TH-4 on intestinal mucositis induced by the chemotherapeutic agent 5-Fluorouracil (5-FU). Cancer Biol Ther 2009; 8: 505-511.
90. Cheah KY, Howarth GS, Yazbeck R,. Grape seed extract protects IEC-6 cells from chemotherapy-induced cytotoxicity and improves parameters of small intestinal mucositis in rats with experimentally-induced mucositis. Cancer Biol Ther 2009; 8: 382-390.
91. Wright TH, Yazbeck R, Lymn KA,. The herbal extract, Iberogast, improves jejunal integrity in rats with 5-Fluorouracil (5-FU)-induced mucositis. Cancer Biol Ther 2009; 8: 923-929.
92. Bajic JE, Eden GL, Lampton LS,. Rhubarb extract partially improves mucosal integrity in chemotherapy-induced intestinal mucositis. World J Gastroenterol 2016; 22: 8322-8333.
93. Chartier LC, Howarth GS, Lawrance IC,. Emu oil improves clinical indicators of disease in a mouse model of colitis-associated colorectal cancer. Dig Dis Sci 2018; 63: 135-145.
94. Jain U, Midgen CA, Woodruff TM,. Properdin deficiency protects from 5-fluorouracil-induced small intestinal mucositis in a complement activation-independent, interleukin-10-dependent mechanism. Clin Exp Immunol 2017; 188: 36-44.
95. Yeung CY, Chan WT, Jiang CB,. Amelioration of chemotherapy-induced intestinal mucositis by orally administered probiotics in a mouse model. PLoS One 2015; 10: e0138746.
96. Justino PF, Melo LF, Nogueira AF,. Treatment with Saccharomyces boulardii reduces the inflammation and dysfunction of the gastrointestinal tract in 5-fluorouracil-induced intestinal mucositis in mice. Br J Nutr 2014; 111: 1611-1621.
97. Kim HJ, Kim JH, Moon W,. Rebamipide attenuates 5-Fluorouracil-induced small intestinal mucositis in a mouse model. Biol Pharm Bull 2015; 38: 179-183.
98. Wu Z, Han X, Qin S,. Interleukin 1 receptor antagonist reduces lethality and intestinal toxicity of 5-fluorouracil in a mouse mucositis model. Biomed Pharmacother 2010; 64: 589-593.
99. Matsumoto K, Nakajima T, Sakai H,. Increased expression of 5-HT3 and NK 1 receptors in 5-fluorouracil-induced mucositis in mouse jejunum. Dig Dis Sci 2013; 58: 3440-3451.
100. Yasuda M, Kato S, Yamanaka N,. 5-HT (3) receptor antagonists ameliorate 5-fluorouracil-induced intestinal mucositis by suppression of apoptosis in murine intestinal crypt cells. Br J Pharmacol 2013; 168: 1388-1400.
101. Huang T, Chu HC, Lin YL,. Minocycline attenuates 5-fluorouracil-induced small intestinal mucositis in mouse model. Biochem Biophys Res Commun 2009; 389: 634-639.
102. Di Paolo A, Bocci G, Danesi R, Del Tacca M,. Clinical pharmacokinetics of irinotecan-based chemotherapy in colorectal cancer patients. Curr Clin Pharmacol 2006; 1: 311-323.
103. Pedroso SH, Vieira AT, Bastos RW,. Evaluation of mucositis induced by irinotecan after microbial colonization in germ-free mice. Microbiology 2015; 161: 1950-1960.
104. Takasuna K, Hagiwara T, Hirohashi M,. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 1996; 56: 3752-3757.
105. Kurita A, Kado S, Matsumoto T,. Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of beta-glucuronidase activity in intestinal lumen. Cancer Chemother Pharmacol 2011; 67: 201-213.
106. Wardill HR, Bowen JM, Al-Dasooqi N,. Irinotecan disrupts tight junction proteins within the gut: implications for chemotherapy-induced gut toxicity. Cancer Biol Ther 2014; 15: 236-244.
107. Gibson RJ, Coller JK, Wardill HR,. Chemotherapy-induced gut toxicity and pain: involvement of TLRs. Support Care Cancer 2016; 24: 2251-2258.
108. Mathijssen RH, Verweij J, de Bruijn P,. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 2002; 94: 1247-1249.
109. Birdsall TC,. St. John's wort and irinotecan-induced diarrhea. Toxicol Appl Pharmacol 2007; 220: 108.
110. Hu ZP, Yang XX, Chan SY,. St. John's wort attenuates irinotecan-induced diarrhea via down-regulation of intestinal pro-inflammatory cytokines and inhibition of intestinal epithelial apoptosis. Toxicol Appl Pharmacol 2006; 216: 225-237.
111. Hu Z, Yang X, Ho PC,. St. John's Wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats. Pharm Res 2005; 22: 902-914.
112. Bastos RW, Pedroso SH, Vieira AT,. Saccharomyces cerevisiae UFMG A-905 treatment reduces intestinal damage in a murine model of irinotecan-induced mucositis. Benef Microbes 2016; 7: 549-557.
113. Mathijssen RH, van Alphen RJ, Verweij J,. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001; 7: 2182-2194.
114. Li J, Yu Q, Fu S,. A novel genetic score model of UGT1A1 and TGFB pathway as predictor of severe irinotecan-related diarrhea in metastatic colorectal cancer patients. J Cancer Res Clin Oncol 2016; 142: 1621-1628.
115. McQuade RM, Carbone SE, Stojanovska V,. Role of oxidative stress in oxaliplatin-induced enteric neuropathy and colonic dysmotility in mice. Br J Pharmacol 2016; 173: 3502-3521.
116. Stojanovska V, McQuade RM, Miller S,. Effects of Oxaliplatin Treatment on the Myenteric Plexus Innervation and Glia in the Murine Distal Colon. J Histochem Cytochem 2018; 66: 723-736.
117. Kaczmarek A, Brinkman BM, Heyndrickx L,. Severity of doxorubicin-induced small intestinal mucositis is regulated by the TLR-2 and TLR-9 pathways. J Pathol 2012; 226: 598-608.
118. Chen YH, Lee YT, Wen CC,. Modeling pegylated liposomal doxorubicin-induced hand-foot syndrome and intestinal mucositis in zebrafish. Onco Targets Ther 2014; 7: 1169-1175.
119. Wang YH, Chen YH, Lin YJ,. Spatiotemporal expression of zebrafish keratin 18 during early embryogenesis and the establishment of a keratin 18:RFP transgenic line. Gene Expr Patterns 2006; 6: 335-339.
120. Ding YJ, Chen YH,. Developmental nephrotoxicity of aristolochic acid in a zebrafish model. Toxicol Appl Pharmacol 2012; 261: 59-65.
121. Wang X, Gao J, Qian L,. Exogenous IL-1Ra attenuates intestinal mucositis induced by oxaliplatin and 5-fluorouracil through suppression of p53-dependent apoptosis. Anticancer Drugs 2015; 26: 35-45.
122. Andreyev J,. Gastrointestinal symptoms after pelvic radiotherapy: a new understanding to improve management of symptomatic patients. Lancet Oncol 2007; 8: 1007-1017.
123. Erlandsson J, Holm T, Pettersson D,. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, nonblinded, phase 3, noninferiority trial. Lancet Oncol 2017; 18: 336-346.
124. Rotolo JA, Kolesnick R, Fuks Z,. Timing of lethality from gastrointestinal syndrome in mice revisited. Int J Radiat Oncol Biol Phys 2009; 73: 6-8.
125. Vanhoecke B, Bateman E, Mayo B,. Dark Agouti rat model of chemotherapy-induced mucositis: establishment and current state of the art. Exp Biol Med (Maywood) 2015; 240: 725-741.
126. Gibson RJ, Bowen JM, Keefe DM,. Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. Int J Cancer 2005; 116: 464-470.
127. Gibson RJ, Keefe DM, Clarke JM,. The effect of keratinocyte growth factor on tumour growth and small intestinal mucositis after chemotherapy in the rat with breast cancer. Cancer Chemother Pharmacol 2002; 50: 53-58.
128. Gibson RJ, Stringer AM, Bowen JM,. Velafermin improves gastrointestinal mucositis following irinotecan treatment in tumor-bearing DA rats. Cancer Biol Ther 2007; 6: 541-547.
129. Gibson RJ, Keefe DM, Thompson FM,. Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci 2002; 47: 2751-2757.
130. Bowen JM, Stringer AM, Gibson RJ,. VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. Cancer Biol Ther 2007; 6: 1449-1454.
131. Coller JK, Bowen JM, Ball IA,. Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report. Cancer Chemother Pharmacol 2017; 79: 431-434.
132. Al-Dasooqi N, Bowen J, Bennett C,. Cell adhesion molecules are altered during irinotecan-induced mucositis: a qualitative histopathological study. Support Care Cancer 2017; 25: 391-398.
133. Al-Dasooqi N, Gibson RJ, Bowen JM,. Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the dark agouti rat. Exp Biol Med (Maywood) 2010; 235: 1244-1256.
134. Thorpe D, Stringer A, Butler R,. Chemotherapy-induced mucositis: the role of mucin secretion and regulation, and the enteric nervous system. Neurotoxicology 2013; 38: 101-105.
135. Stringer AM, Gibson RJ, Logan RM,. Irinotecan-induced mucositis is associated with changes in intestinal mucins. Cancer Chemother Pharmacol 2009; 64: 123-132.
136. Stansborough RL, Al-Dasooqi N, Bateman EH,. Matrix metalloproteinase expression is altered in the small and large intestine following fractionated radiation in vivo. Support Care Cancer 2018; doi: 10.1007/s00520-018-4255-5. [Epub ahead of print].
137. Stansborough RL, Bateman EH, Al-Dasooqi N,. Vascular endothelial growth factor (VEGF), transforming growth factor beta (TGFbeta), angiostatin, and endostatin are increased in radiotherapy-induced gastrointestinal toxicity. Int J Radiat Biol 2018; 94: 645-655.
138. Sangild PT, Shen RL, Pontoppidan P, Rathe M,. Animal models of chemotherapy-induced mucositis: translational relevance and challenges. Am J Physiol Gastrointest Liver Physiol 2018; 314: G231-G246.
139. Bauer J, Jurgens H, Fruhwald MC,. Important aspects of nutrition in children with cancer. Adv Nutr 2011; 2: 67-77.
140. Bateman E, Bowen J, Stringer A,. Investigation of effect of nutritional drink on chemotherapy-induced mucosal injury and tumor growth in an established animal model. Nutrients 2013; 5: 3948-3963.
141. Bowen JM,. Development of the rat model of lapatinib-induced diarrhoea. Scientifica (Cairo) 2014; 2014: 194185.
142. Bowen JM, Mayo BJ, Plews E,. Determining the mechanisms of lapatinib-induced diarrhoea using a rat model. Cancer Chemother Pharmacol 2014; 74: 617-627.
143. Hare KJ, Hartmann B, Kissow H,. The intestinotrophic peptide, glp-2, counteracts intestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, gefitinib. Clin Cancer Res 2007; 13: 5170-5175.
144. Rasmussen AR, Viby NE, Hare KJ,. The intestinotrophic peptide, GLP-2, counteracts the gastrointestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, erlotinib, and cisplatin. Dig Dis Sci 2010; 55: 2785-2796.
145. Van Sebille YZA, Gibson RJ, Wardill HR,. Dacomitinib-induced diarrhoea is associated with altered gastrointestinal permeability and disruption in ileal histology in rats. Int J Cancer 2017; 140: 2820-2829.
146. Van Sebille YZA, Gibson RJ, Wardill HR,. Dacomitinib-induced diarrhea: targeting chloride secretion with crofelemer. Int J Cancer 2018; 142: 369-380.
147. Wardill HR, Bowen JM, Van Sebille YZ,. TLR4-dependent claudin-1 internalization and secretagogue-mediated chloride secretion regulate irinotecan-induced diarrhea. Mol Cancer Ther 2016; 15: 2767-2779.
148. Frank M, Hennenberg EM, Eyking A,. TLR signaling modulates side effects of anticancer therapy in the small intestine. J Immunol 2015; 194: 1983-1995.
149. Soares PM, Mota JM, Souza EP,. Inflammatory intestinal damage induced by 5-fluorouracil requires IL-4. Cytokine 2013; 61: 46-49.
150. Wong DV, Lima-Junior RC, Carvalho CB,. The adaptor protein Myd88 is a key signaling molecule in the pathogenesis of irinotecan-induced intestinal mucositis. PLoS One 2015; 10: e0139985.
151. Leitao RF, Brito GA, Oria RB,. Role of inducible nitric oxide synthase pathway on methotrexate-induced intestinal mucositis in rodents. BMC Gastroenterol 2011; 11: 90.
152. Alexander JL, Wilson ID, Teare J,. Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat Rev Gastroenterol Hepatol 2017; 14: 356-365.
153. Gao J, Gao J, Qian L,. Activation of p38-MAPK by CXCL4/CXCR3 axis contributes to p53-dependent intestinal apoptosis initiated by 5-fluorouracil. Cancer Biol Ther 2014; 15: 982-991.
154. Lu H, Liu H, Wang J,. The chemokine CXCL9 exacerbates chemotherapy-induced acute intestinal damage through inhibition of mucosal restitution. J Cancer Res Clin Oncol 2015; 141: 983-992.
155. Schook LB, Collares TV, Darfour-Oduro KA,. Unraveling the swine genome: implications for human health. Annu Rev Anim Biosci 2015; 3: 219-244.
156. Xiao L, Estelle J, Kiilerich P,. A reference gene catalogue of the pig gut microbiome. Nat Microbiol 2016. 16161. [Epub ahead of print].
157. Appelbaum FR, Deeg HJ, Storb R,. Marrow transplant studies in dogs with malignant lymphoma. Transplantation 1985; 39: 499-504.
158. Gupta YK, Sharma SS,. Antiemetic activity of antioxidants against cisplatin-induced emesis in dogs. Environ Toxicol Pharmacol 1996; 1: 179-184.
159. Sotocinal SG, Sorge RE, Zaloum A,. The Rat Grimace Scale: a partially automated method for quantifying pain in the laboratory rat via facial expressions. Mol Pain 2011; 7: 55.
160. De Rantere D, Schuster CJ, Reimer JN,. The relationship between the Rat Grimace Scale and mechanical hypersensitivity testing in three experimental pain models. Eur J Pain 2015; 20: 417-426.
161. Deuis JR, Dvorakova LS, Vetter I,. Methods used to evaluate pain behaviors in rodents. Front Mol Neurosci 2017; 10: 284.
162. Bowen JM, Gibson RJ, Keefe DM,. Animal models of mucositis: implications for therapy. J Support Oncol 2011; 9: 161-168.
163. Barzal JA, Szczylik C, Rzepecki P,. Plasma citrulline level as a biomarker for cancer therapy-induced small bowel mucosal damage. Acta Biochim Pol 2014; 61: 615-631.
164. Fijlstra M, Rings EH, Verkade HJ,. Lactose maldigestion during methotrexate-induced gastrointestinal mucositis in a rat model. Am J Physiol Gastrointest Liver Physiol 2011; 300: G283-G291.
165. Hugenholtz F, de Vos WM,. Mouse models for human intestinal microbiota research: a critical evaluation. Cell Mol Life Sci 2018; 75: 149-160.
166. Franklin CL, Ericsson AC,. Microbiota and reproducibility of rodent models. Lab Anim (NY) 2017; 46: 114-122.
167. Ley RE, Backhed F, Turnbaugh P,. Obesity alters gut microbial ecology. Proc Natl Acad Sci USA 2005; 102: 11070-11075.
168. Ley RE, Peterson DA, Gordon JI,. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 2006; 124: 837-848.
169. Eckburg PB, Relman DA,. The role of microbes in Crohn's disease. Clin Infect Dis 2007; 44: 256-262.
170. Wardill HR, Bowen JM, Van Sebille YZA,. Routine assessment of the gut microbiome to promote preclinical research reproducibility and transparency. Gut 2017; 66: 1869-1871.
171. Vanlancker E, Vanhoecke B, Stringer A,. 5-Fluorouracil and irinotecan (SN-38) have limited impact on colon microbial functionality and composition in vitro. PeerJ 2017; 5: e4017.